Novocure NVCR announced today that the U.S. Food and Drug
Administration (FDA) has approved Optune in combination with
temozolomide for the treatment of adult patients with newly diagnosed
glioblastoma (GBM). Optune is a portable, non-invasive device that
delivers low-intensity, intermediate frequency, alternating electric
fields – referred to as Tumor Treating Fields (TTFields) – that inhibit
cancer cell replication and cause cancer cell death.
Optune is the first FDA-approved therapy in more than a decade to
demonstrate statistically significant extension of overall survival in
newly diagnosed GBM. The two-year survival rate among patients treated
with Optune in combination with temozolomide was 50% higher than in
patients treated with temozolomide alone. No significant additive
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in